Fulltext

Measurement of plasma endothelin-1 in experimental hypertension and in healthy subjects

Abdel-Sayed, Saad ; Nussberger, Juerg ; Aubert, Jean-François ; Gohlke, Peter ; Brunner, Hans Rudolf ; Brakch, Noureddine

In: American Journal of Hypertension, 2003, vol. 16, no. 7, p. 515-521

Ajouter à la liste personnelle
    Titre
    • Measurement of plasma endothelin-1 in experimental hypertension and in healthy subjects
    Auteur
    • Abdel-Sayed, Saad. Division of Hypertension and Vascular Medicine, University Hospital Lausanne Lausanne, Switzerland
    • Nussberger, Juerg. Division of Hypertension and Vascular Medicine, University Hospital Lausanne Lausanne, Switzerland
    • Aubert, Jean-François. Division of Hypertension and Vascular Medicine, University Hospital Lausanne Lausanne, Switzerland
    • Gohlke, Peter. Institute of Pharmacology, University Hospital of Schleswig-Holstein, Kiel, Germany
    • Brunner, Hans Rudolf. Division of Hypertension and Vascular Medicine, University Hospital Lausanne Lausanne, Switzerland
    • Brakch, Noureddine. Division of Hypertension and Vascular Medicine, University Hospital Lausanne Lausanne, Switzerland
    Type de document
    • Postprint
    Identifiant OAI-PMH
    • oai:doc.rero.ch:304268
    Summary
    Background: Endothelin-1 is an endothelium-derived potent vasoconstrictor peptide of 21 amino acids. To establish reference values in different models of hypertension and in human subjects an assay for plasma immunoreactive endothelin-1 (ET-1) was optimized. Methods: ET-1 is extracted by acetone from 1 mL of plasma and subjected to a sensitive enzyme-linked immunosorbent assay. Results: The detection limit for plasma ET-1 is 0.05 fmol/mL. Mean recoveries of the 1, 2, 5, and 10 fmol of ET-1 added to 1 mL of plasma were 66%, 75%, 85%, and 92%, respectively. Within- and between-assay coefficients of variation were ≤12% and ≤10%, respectively. Assay accuracy was demonstrated by consistent recoveries of added ET-1 over the entire physiologic range of plasma concentrations and by the linearity of ET-1 concentrations measured in serially diluted plasma extracts (r = 0.99). No ET-1 was detected when albumin buffer was extracted instead of plasma. Using this method, we found increased ET-1 levels in plasma of three experimental rat models of hypertension: stroke prone spontaneously hypertensive rats (SP-SHR), deoxycorticosterone acetate-salt hypertensive rats, and one kidney-one clip hypertensive rats. In contrast, plasma ET-1 levels of SHR were half those of normotensive Wistar rats. In two kidney-one clip hypertensive rats, plasma ET-1 concentrations were not different from those found in sham-operated control rats. Plasma ET-1 concentrations of 37 healthy men were 0.85 ± 0.26 fmol/ml (mean ± SD). Conclusions: The present assay reliably measures ET-1 levels in rat and human plasma. It allows to discriminate between different forms of hypertension with high or low circulating levels of ET-1. Am J Hypertens 2003;16: 515-521 @ 2003 American Journal of Hypertension, Ltd